Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.51 |
| ▸ | CDK1 | P06493 | 15/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582577 | 1.00 | AURKA (0.51) | AURKACDK1CCNB1CYP3A4CYP2C9 | |
| SCHEMBL3588626 | 0.84 | AURKA (0.54) | AURKACDK1CCNB1CYP3A4CYP2C9 | |
| SCHEMBL3585045 | 0.84 | AURKA (0.54) | AURKACDK1CCNB1CYP3A4CYP2C9 | |
| SCHEMBL3585042 | 0.84 | AURKA (0.54) | AURKACDK1CCNB1CYP3A4CYP2C9 | |
| SCHEMBL3580556 | 0.83 | ABL1 (0.39) | AURKACDK1CCNB1CDK4JAK3 | |
| SCHEMBL3590707 | 0.83 | ABL1 (0.39) | AURKACDK1CCNB1CDK4JAK3 | |
| SCHEMBL3592265 | 0.83 | ABL1 (0.39) | AURKACDK1CCNB1CDK4JAK3 | |
| SCHEMBL3589173 | 0.82 | GSK3B (0.43) | AURKAJAK2 | |
| SCHEMBL3588605 | 0.82 | GSK3B (0.43) | AURKAJAK2 | |
| SCHEMBL3588602 | 0.82 | GSK3B (0.43) | AURKAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | AURKA 10/4885CDK1 1/4885CCNB1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.